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An objective assessment of the variability
in number of drops per bottle of glaucoma
medication
Daniel B. Moore1*, Judy Beck1 and Richard J Kryscio2

Abstract
Background: The purpose of this study is to evaluate the number of eyedrops available per bottle of a variety of
commonly prescribed glaucoma medications.
Methods: Six bottles of each glaucoma medication were tested: three each in the vertical and horizontal
orientations. Bottles were housed in a customized force gauge apparatus designed to mimic ballpoint fingertip
contact with a bottle. At a standard rate, all drops were expressed from each bottle and counted with an
automated drop counter. Simultaneously, bottle volume was measured and drop size and number were also
estimated. The main outcome measures were: total number of drops, volume per bottle and drops per milliliter
(mL) of glaucoma medication.
Results: A total of 192 bottles from 32 bottle designs and manufacturers were tested. Twenty-two of the 32 bottle
designs had a significantly different mean number of drops in the vertical and horizontal positions, with 10 designs
have more drops dispensed in the horizontal orientation and 12 in the vertical orientation. Six of the 32 bottle designs
had a significantly different mean total bottle volume in the vertical and horizontal positions, with all designs having
greater volume in the vertical position. An adjusted ratio of mean number of drops/mean bottle volume demonstrated
a range from 20.9 drops/mL to 40.8 drops/mL.
Conclusions: There is significant variability in drops and volume available per bottle of glaucoma medication
depending on both the bottle position and manufacturer. These data point to the need for circumspection in
prescribing glaucoma medications and caution in evaluating therapeutic outcomes.
Keywords: Glaucoma, Pharmacology, Therapeutics, Eyedrop, Compliance, Bottle

Background
Although data demonstrate improved outcomes with
lowered intraocular pressure from appropriate pharmacotherapy [1, 2], many patients with glaucoma struggle
to adhere to their prescribed regimens. Several studies
suggest patients comply with 70% or fewer of their glaucoma medications [3–5]. Many factors have been implicated [6], but difficulty instilling drops has garnered
recent attention [7]. Proper eyedrop administration
requires eye-hand coordination and dexterity, linking
visual acuity with a steady hand and accurate
* Correspondence: daniel.b.moore@uky.edu
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740 S. Limestone, Lexington, KY 40536, USA
Full list of author information is available at the end of the article

proprioception [8]. Not surprisingly, videotape evidence
demonstrated that glaucoma patient used an average
of 1.4–1.8 drops when trying to instill a single eyedrop [9, 10]. A recent cross-sectional patient survey
revealed that 25% of patients reported problems with early
eyedrop bottle exhaustion and associated compliance with
therapy. One-third of patients reported the reason for
early bottle exhaustion was due to bottle related problems
such as “more than one drop comes out” or “size of drops
is too large”. The latter complaint is supported by literature that demonstrates the volume of an eyedrop in an
ophthalmic solution may vary from 25 to 70 μl [11]. Given
the normal tear film volume is 7 μl and only capable of
containing 30 μl without overflow, a significant portion of
an eyedrop is wasted [12]. These data suggest that a
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significant number of glaucoma patients run out of eyedrops prior to a scheduled prescription refill and that bottle related mechanics play a role [13].
Despite the importance of bottle design in proper use
of topical therapeutics, there exists no standardization of
manufacture in regards to drop instillation dynamics
[14], and the only dosing requirement is to accurately
label and package medication volume [15]. Being manufactured and sold on the basis of volume, eyedrops are
distinct from most other forms of pharmacotherapy,
which are prescribed with a discrete number of doses to
guide dispensing and refill rates. While the minimum
volume of medication consumers should anticipate per
container of medication is available, this does not necessarily translate to number of applications, and without
regulation, leads to the possibility of inconsistency in the
number of drops of medicine available per bottle. Several
previous studies evaluating a smaller number of medications in a non-standardized fashion have found significant variability in the number of drops between both
brands of medication and position of the bottle [16–18].
As such, the current study was designed to further
evaluate this possibility by objectively and systematically
measuring the number of eyedrops in each bottle of
many common glaucoma medications.

Methods
The number of eyedrops dispensed from various common glaucoma medications was measured. All medications were purchased at cost from the University of
Kentucky Research Pharmacy and represented available
regional brand and generic medications. A force gauge
apparatus consisting of a Mecmesin M500E Motorised
Tension and Compression Test Stand, Mecmesin 100 N
Advanced Force Gauge (Mecmesin Corporation, Sterling,
VA, USA) and custom grips and compressors were designed
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and calibrated by JA King & Company (Whitsett, NC,
USA) (Fig. 1). The compressors were designed to mimic
ballpoint fingertip contact with a bottle. For each medication, the bottle was housed in the apparatus and
clamps were adjusted until the ballpoint compressors
were located at mid bottle length. For bottles with a
rectangular instead of round shape, the thinner dimensions were chosen for compression, as this represents
the method most likely to be utilized by patients when
instilling drops. Starting at 0 kg-force (kgf ) and 0 mm
(mm) displacement, the gauge was advanced in 0.1 mm
increments until a drop of liquid fell from the bottle,
as observed subjectively and confirmed with an automated VCD-BTD drop counter (Vernier Software and
Technology, Beaverton, OR, USA) and LabQuest 2
display (Vernier Software and Technology, Beaverton, OR,
USA). At a rate of approximately one drop/s, 10 drops
were expressed, then the apparatus was retracted to 0 kgf.
This was repeated until all drops were exhausted from
the bottle.
Simultaneously, drop size and number was also estimated using the densitometric method for volume determination [19]. In twenty drop increments, the total volume
of solution expressed was measured with a 0.0001 g
analytical balance (Ohaus Corporation, Parsippany, NJ,
USA). This was repeated until all drops were exhausted
from the bottle. A 200 uL pipette (Zhejiang Huawei
Scientific Instrument Co, LTD, Zhe Jiang, China) was
used to remove four 100-uL aliquots of each bottle.
The mean of the samples was divided by 0.1 mL to estimate the volume of each drop and each bottle by dividing
the mass of each by the calculated density. For any bottles
with residual liquid in the container lid, this was removed
with the pipette and volume was measured separately.
Six bottles of each medication were tested. Three bottles were tested in the vertical orientation with the bottle

Fig. 1 Force Gauge Apparatus. A force gauge apparatus consisting of a Mecmesin M500E Motorized Tension and Compression Stand, Mecmesin
100 N Advanced Force Gauge and custom grips and compressors were designed and calibrated by JA King & Company. a: The compressors were
designed to mimic ballpoint fingertip contact with a bottle tip. b: For each medication, the bottle was housed in the apparatus and clamps were
adjusted until the ballpoint compressors were located at mid bottle length. The L-shaped compression clamp was then adjusted until the force gauge
sensor was centered on the crosshairs of the clamp at a 90-degree angle
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Table 1 Description of Glaucoma Medications Tested
Medication Name

Formulation

Manufacturer

Travatan

travaprost 0.004%

Alcon Laboratories, Inc. Fort Worth, TX 76134

Travaprost

travaprost 0.004%

Par Pharmaceutical Cos. Inc. Spring Valley, NY 10977

Xalatan

latanoprost 0.005%

Pharmacia&Upjohn Co, Division of Pfizer, Inc. NY, NY 10017

Latanoprost

latanoprost 0.005%

Akorn, Inc. Lake Forest, IL 60045

Lumigan

bimatoprost 0.001%

Allergan, Inc. Irvine, CA 92612

Lumigan

bimatoprost 0.001%

Allergan, Inc. Irvine, CA 92612

Travaprost

travaprost 0.004%

Par Pharmaceutical Cos. Inc. Spring Valley, NY 10977

Travatan

travaprost 0.004%

Alcon Laboratories, Inc. Fort Worth, TX 76134

Alphagan P 0.1%

brimonidine tartrate 0.1%

Allergan, Inc. Irvine, CA 92612

Combigan

brimonidine tartrate 0.2%,
timolol maleate 0.5%

Allergan, Inc. Irvine, CA 92612

timolol maleate 0.5%

Pacific Pharma, Irvine CA, 92,612

Timolol Hi-Tech

timolol maleate 0.5%

Hi-Tech Pharmacal Co, Inc. Amityville, NY 11701

Timolol Sandoz

timolol maleate 0.5%

Alcon Laboratories, Inc. Fort Worth, TX 76134 for Sandoz Inc.
Pricenton, NJ 08540

Betimol

timolol maleate 0.5%

Akorn, Inc. Lake Forest, IL 60045 for Oak Pharmaceuticals, Inc.

Timoptic XE

timolol maleate 0.5%

Merck Sharp & Dohme-Chibret 63,963 Clermont-Ferrand Cedex
9, France; Distributed by Valeant Ophthalmics, a division of
Valeant Pharmaceuticals North America LLC,
Bridgewater, NJ 08807

Timoptic

timolol maleate 0.5%

Merck Sharp & Dohme-Chibret 63,963 Clermont-Ferrand Cedex
9, France; Distributed by Valeant Ophthalmics,
a division of Valeant Pharmaceuticals
North America LLC, Bridgewater, NJ 08807

Istalol

timolol maleate 0.5%

Bausch&Lomb Incorporated Tampa, FL 33637 under License
from Senju Pharmaceutical Co, Ltd. Osaka, Japan 541–0046

bimatoprost 0.001%

Allergan, Inc. Irvine, CA 92612

brinzolamide 1%, brimonidine
tartrate 0.2%

Alcon Laboratories, INC 6201 South Freeway, Fort Worth, TX 76134

Cosopt

dorzolamide HCL 22.3 mg/ml,
timolol maleate 6.8 mg/ml

Akorn, Inc. Lake Forest, IL 60045

Dorz/Tim Hi-Tech

dorzolamide HCL 22.3 mg/ml,
timolol maleate 6.8 mg/ml

Hi-Tech Pharmacal Co, Inc. Amityville, NY 11701

Dorz/Tim Bausch

dorzolamide HCL 22.3 mg/ml,
timolol maleate 6.8 mg/ml

Bausch & Lomb Incorporated Tampl, FL 33637

Dorz/Tim Sandoz

dorzolamide HCL 22.3 mg/ml,
timolol maleate 6.8 mg/ml

Alcon Laboratories Inc. Fort Worth Tx 76,134 for Sandoz Inc.
Princeton, NJ 08540

Trusopt

dorzolamide HCL 2%

Merck Sharp & Dohme Corp.,a subsidiary of Merck & Co, Inc.
Whitehouse Station, NJ 08889

Dorz Hi Tech

dorzolamide HCL 2%

Hi-Tech Pharmacal Co, Inc. Amityville, NY 11701

Dorz Bausch

dorzolamide HCL 2%

Bausch & Lomb Incorporated Tampa, FL 33637

Dorz Teva

dorzolamide HCL 2%

Teva Pharmaceutical Ind, Ltd. Jerusalem, 91,010, Israel for Teva
Pharmaceuticals USA Sellersville, PA 18960

Dorz Sandoz

dorzolamide HCL 2%

Alcon Laboratires, Inc. Fort Worth, TX 76134 for Sandoz Inc.
Princeton, NJ 08540

2.5 ml

5 ml

Timolol

Pacific

7.5 ml
Lumigan
8 ml
Simbrinza
10 ml
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Table 1 Description of Glaucoma Medications Tested (Continued)
Azopt

brinzolamide 1%

Alcon Laboratories, Inc. Fort Worth, TX 76134

Combigan

brimonidine tartrate 0.2%, timolol maleate 0.5%

Allergan, Inc. Irvine, CA 92612

Alphagan P 0.15%

brimonidine tartrate 0.15%

Allergan, Inc. Irvine, CA 92612

Alphagan P 0.1%

brimonidine tartrate 0.1%

Allergan, Inc. Irvine, CA 92612

The medication name and volume used in the study, the formulation and manufacturer are listed

tip at 180 degrees and three bottles were tested in the
near horizontal orientation with the bottle tip at 30
degrees. The vertical and horizontal orientations were
the starting position for the bottle tip during each measurement, as compression of the bottle variably and
slightly changed the tip position.
Statistical analysis

Mean response was compared by constructing an analysis of variance for a two way layout with factors:
position (horizontal versus vertical) and bottle (all combinations of medication name and formulation). A highly
significant interaction between position and bottle was
obtained (p < 0.0001). Post hoc comparison of means
was done by comparing means between positions for
each bottle by using two sample t-tests. To compare different bottle designs in the same orientation, Fisher’s
least significant differences allowance was computed.
Statistical significance was determined at the 0.01 level
to minimize the Type I error rate.

Results
A total of 192 bottles from 32 bottle designs and manufacturers of medication were tested (Table 1). Further
reference to medications will include brand name,
manufacturer if more than one generic and bottle
volume for identification. Fifteen formulations came
from the same lot, sixteen came from a combination of
two different lots and one came from a combination of
three different lots. When comparing the mean value of
variance between formulations from the same or different lots, there was no statistical difference (p = 0.62).
Comparing mean number of drops per bottle using
observed measurements versus the densitometric method
to calculate number of drops in the bottle, there was no
difference in the vertical (p = 0.35, paired t-test), but
a significant difference between measurements in the
horizontal (p = 0.02, paired t-test) position. Observed
measurements via the automated drop counter were
used for subsequent analysis.
The mean number and standard deviation of drops per
bottle in the horizontal, vertical and summative positions
of all formulations are provided in Table 2. For
2.5 mL bottles, the mean number of drops ranged
from 75.3–101.7 and 72–102.3 in the vertical and

horizontal orientations, respectively. For 5 mL bottles, the
range was 111–209.3 and 115–189 drops in the vertical
and horizontal orientations, respectively. For 10 mL bottles, the range was 193.7–313.3 and 234–323.7 drops in
the vertical and horizontal orientations, respectively.
Twenty-two of the 32 bottle designs had a significantly
different mean number of drops in the vertical and horizontal positions, with 10 designs have more drops dispensed in the horizontal orientation and 12 in the vertical.
The mean bottle and drop volume are also listed in
Table 2. Bottle volumes were measured with and without
accounting for residual volume in the cap of the container, with less than a 2.2% difference of the overall
mean in 90% of the bottles. Presented bottle volume
measurements include the cap volume. For 2.5 mL bottles, the range was 2.37–2.69 mL and 2.38–2.70 mL in
the vertical and horizontal orientations, respectively. For
5 mL bottles, the range was 4.72–5.93 mL and
4.67–5.66 mL in the vertical and horizontal orientations,
respectively. For 10 mL bottles, the range was
8.93–10.2 mL and 8.38–9.79 mL in the vertical and horizontal orientations, respectively. Six of the 32 bottle
designs had a significantly different mean total bottle
volume in the vertical and horizontal positions, with all
designs having greater volume in the vertical position.
There were no significant differences between the horizontal and vertical measured drop volume for any designs.
Given the multiple different comparisons possible
between bottle type, size and volume, an adjusted ratio
of mean number of drops/mean bottle volume was
created (Table 2), with a range from 20.9 drops/mL to
40.8 drops/mL among the bottle designs and positions.
Nineteen formulations had a significantly different ratio
between the horizontal and vertical positions (p < 0.01).
For comparing means between two bottle designs in the
same orientation, any two means that differ by a value of
5.27 or greater are significantly different (p < 0.01).

Discussion
The results of this study suggest there is significant variability in the number of drops and volume per bottle of
glaucoma medications, both in terms of which bottle
design and manufacturer is utilized and the position the
bottle is held when squeezed. For example, if a representative patient from this region is prescribed a 5 mL
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Table 2 Mean Number of Drops, Volume and Drop/Volume Ratio per Glaucoma Medication Tested
Drop

Mean # Drops
vert

Mean Bottle Volume

horz

p value vert

horz

<0.01

p value

Mean Drop
Volume

Mean Drops/mL

vert

vert

horz

horz

p value

2.5 ml
Travatan

76.3 ± 4.2

102.3 ± 1.5

2.57 ± 0.07

2.53 ± 0.04

0.032 0.025 29.66 ± 1.35

40.4 ± 1.07

0.0004

Travaprost

75.3 ± 5.1

72 ± 1

2.46 ± 0.04

2.36 ± 0.07

0.032 0.032 30.6 ± 2.51

30.47 ± 1.14

0.9445

Xalatan

101.3 ± 0.6

83.3 ± 3.1

2.69 ± 0.05

2.70 ± 0.05

0.027 0.032 37.68 ± 0.73

30.90 ± 0.60

0.0002

Latanoprost

86.7 ± 9.3

76.7 ± 5.0

2.37 ± 0.26

2.42 ± 0.13

0.027 0.032 36.59 ± 0.98

31.63 ± 0.76

0.0023

Lumigan

101.7 ± 2.3

81.7 ± 4.0

2.50 ± 0.05

2.38 ± 0.08

0.024 0.029 40.61 ± 0.18

34.25 ± 0.63

<0.0001

overall mean

88.3

83.2

2.52

2.48

0.029 0.03

overall median

91

81

2.53

2.46

0.027 0.031

overall ST DEV

12.7

11.08

0.15

0.15

0.004 0.003

Lumigan

195.6 ± 4.2

155 ± 1

<0.01

4.97 ± 0.06

4.73 ± 0.06

0.025 0.03

32.75 ± 0.22

<0.001

Travaprost

150.3 ± 6.5

139.7 ± 13.7

4.91 ± 0.02

4.78 ± 0.24

0.032 0.035 30.62 ± 1.42

29.15 ± 1.50

0.2859

Travatan

146.3 ± 0.6

189 ± 1

<0.01

4.8 ± 0.04

4.78 ± 0.07

0.033 0.026 30.49 ± 0.82

29.66 ± 1.35

0.0004

Alphagan P

111 ± 1

117 ± 2.6

4.89 ± 0.05

4.72 ± 0.18

0.044 0.04

Combigan

148 ± 2

161.3 ± 3.8

5.02 ± 0.16

4.67 ± 0.07

<0.01

5 ml

0.01

39.4 ± 0.69

24.82 ± 0.78

0.0102

0.033 0.029 25.26 ± 1.53

22.7 ± 0.16

34.57 ± 0.50

0.0003

25.21 ± 0.09

0.0206

Timolol Pacific

123 ± 1

147.7 ± 9.6

<0.01

4.88 ± 0.04

4.69 ± 0.10

0.04

Timolol Hi-Tech

126.7 ± 6.7

149.3 ± 4.0

<0.01

5.09 ± 0.15

5.04 ± 0.13

0.041 0.034 24.89 ± 0.56

0.031 25.21 ± 0.09

29.61 ± 0.633 0.0006

Timolol Sandoz

161.3 ± 3.5

156.3 ± 2.5

4.89 ± 0.04

4.84 ± 0.08

0.03

Betimol

165.3 ± 0.6

160.7 ± 1.2

5.17 ± 0.035 5.08 ± 0.06

Timoptic XE

130.7 ± 7.5

115 ± 9.8

0.004

5.53 ± 0.24

4.9 ± 0.24

Timoptic

209.3 ± 5.7

155.3 ± 7.1

<0.01

5.93 ± 0.03

5.66 ± 0.03

Istalol

154.6 ± 2.1

165.6 ± 2.5

4.72 ± 0.03

4.74 ± 0.09

0.03

overall mean

151.9

151

5.06

4.89

0.039 0.033

overall median

149

155.2

4.93

4.78

0.033 0.031

overall ST DEV

28.2

20.26

0.34

0.28

0.03

294 ± 2.6

236 ± 2

<0.01

7.21 ± 0.06

7.18 ± 0.03

0.024 0.03

180.7 ± 3.1

219.7 ± 6.7

<0.01

7.51 ± 0.03

301.7 ± 39.6 242 ± 12.5

<0.01

Dorz/Tim Hi-Tech 303 ± 1
Dorz/Tim Bausch 313.3 ± 1.5
Dorz/Tim Sandoz 315 ± 4.6

271.3 ± 5.8

0.031 33.02 ± 0.92

32.28 ± 0.21

0.2459

0.031 0.031 32.00 ± 0.14

31.63 ± 0.56

0.3282

0.042 0.043 23.71 ± 2.41

23.45 ± 1.16

0.8734

27.6 ± 1.21

0.0008

34.95 ± 0.32

0.0006

40.76 ± 0.56

32.85 ± 0.18

<0.001

6.74 ± 0.12

0.0004 0.167 0.031 24.07 ± 0.47

32.58 ± 1.22

0.0003

10.2 ± 0.17

9.58 ± 0.18

0.01

0.033 0.039 29.56 ± 3.66

25.26 ± 1.53

0.1341

251.7 ± 10.0 <0.01

9.23 ± 0.34

9.19 ± 0.26

0.031 0.038 32.85 ± 1.22

27.39 ± 0.39

0.0018

293.7 ± 1.5

<0.01

9.22 ± 0.23

8.91 ± 0.21

0.03

0.031 34.01 ± 0.92

32.96 ± 0.65

0.1804

<0.01

8.93 ± 0.15

8.39 ± 0.29

0.115 0.031 35.27 ± 1.09

32.37 ± 1.03

0.0288

<0.01

10.18 ± 0.20 9.60 ± 0.33

0.221 0.051 30.77 ± 1.86

24.59 ± 0.94

0.0068

0.0003 0.089 0.036 35.28 ± 0.82
0.029 32.77 ± 0.22

0.005

7.5 ml
Lumigan
8 ml
Simbrinza
10 ml
Cosopt

Trusopt

313.3 ± 20.0 236 ± 5.6

Dorz Hi Tech

292.7 ± 10.3 261.7 ± 12.9 <0.01

9.54 ± 0.19

9.13 ± 0.29

0.033 0.035 20.92 ± 17.91 28.70 ± 2.21

0.5313

Dorz Bausch

289.7 ± 4.2

289 ± 4.6

9.18 ± 0.26

8.78 ± 0.15

0.032 0.03

0.0594

Dorz Teva

282 ± 11.5

260 ± 1

<0.01

9.31 ± 0.58

8.69 ± 0.12

0.033 0.034 30.33 ± 0.79

29.91 ± 0.31

0.4423

Dorz Sandoz

193.7 ± 3.79 253.7 ± 15.3 <0.01

9.19 ± 0.12

8.38 ± 0.08

0.0006 0.332 0.034 21.06 ± 0.16

30.26 ± 1.94

0.014

Azopt

254.3 ± 2.1

<0.01

9.42 ± 0.08

8.59 ± 0.04 <0.0001 0.037 0.027 27.01 ± 0.38

37.5 ± 1.08

<0.001

Combigan

270.3 ± 28.4 323.7 ± 17.8 <0.01

9.86 ± 0.21

9.79 ± 0.07

33.07 ± 1.64

0.0303

322 ± 8.9

0.034 0.03

31.55 ± 0.61

27.4 ± 2.50

32.91 ± 0.06
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Table 2 Mean Number of Drops, Volume and Drop/Volume Ratio per Glaucoma Medication Tested (Continued)
Alphagan 0.15%

212.7 ± 3.1

234 ± 3.6

<0.01

9.78 ± 0

9.53 ± 0.09

0.046 0.041 21.75 ± 0.31

24.56 ± 0.16

0.0002

<0.01

24.80 ± 0.41

0.0002

Alphagan 0.1%

216 ± 4

283.3 ± 5.5

9.93 ± 0.19

9.61 ± 0.07

0.046 0.037 21.75 ± 0.11

overall mean

273.7

267.5

9.54

9.09

0.079 0.034

overall median

290

261

9.51

9.02

0.034 0.033

overall ST DEV

42.69

31.07

0.45

0.51

0.119 0.005

The mean number of drops, bottle volume, drop volume and ratio of mean number of drops per bottle volume of three bottles tested for each medication in the
vertical and horizontal positions. Medications are grouped by volume and an overall mean, median and standard deviation for all medications of similar volumes
are provided. A p-value for medications with a significant difference in mean drop number between the horizontal and vertical position is listed, with significance
determined at p = 0.01. A ratio of mean number of drops/mean bottle volume is listed, and any two means that differ by a value of 5.27 or greater are
significantly different (p < 0.01). Volume measurements are in milliliters (mL). A bold value indicates a p value of statistical significance

bottle of timolol 0.5%, there are 5 different generic and
brand bottle designs that may be dispensed. The patient
could anticipate a range of 123–209 and 147–166 mean
drops per bottle in the horizontal and vertical positions,
respectively. If instilled twice daily, this would suggest a
difference between 25.5 to 43 days of available medication depending on the manufacturer and bottle position.
This study is the first to our knowledge to present an
objective, automated and reproducible method to measure the number of drops available per bottle of medication. Further, we measured countable drops instead of
calculating the number of drops based on volume, which
was shown to be inaccurate. Several previous studies
have evaluated small samples of bottle formulations with
similar, variable results. A 1994 study of patients blinded
to either use of a 5 mL bottle of timolol maleate versus
levobunolol found a 21% greater length of use of timolol
(37 versus 29 days) [16]. Another study evaluated 45 versus 90 degree administration of artificial tear bottles and
found a significantly greater number of drops per bottle
using densitometric analysis and smaller drop volume
for 4 out of 5 formulations at 45 compared to 90 degrees.
The authors suggest administration at 45 degrees would
result in up to $1.93 savings per bottle compared to 90
degrees [17]. A study evaluating 2.5 ml bottles of prostaglandin analogues held vertically, at 45 degrees and horizontally found that vertical instillation resulted in more
drops per bottle for bimatoprost and latanoprost, while 45
degrees was most efficient for travaprost. Assuming 1 year
of bilateral therapy at 2006 costs, the authors determined
use of the most efficient instillation method would result
in yearly savings of $109–192 [18]. Lastly, a recent study
found significant variability in the number of eyedrops per
bottle of four regionally available formulations of latanoprost when measured by manually counting the number
of drops expressed by hand, ranging from 77.6 to 88.7
drops per bottle. The authors estimated a similarly significant difference in estimated annual cost, ranging from
$184 to $1198 per formulation [20].
Currently, there exist no federal guidelines to regulate
bottle design or amount of drops available per volume of
medication [14, 15]. It has been suggested that pharmacists

often use a rough guideline of 0.05 mL per eyedrop or 20
drops per mL (written personal communication, Division
of Drug Information, FDA, March 27, 2015). With that in
mind, there are significantly more eyedrops per bottle in
this analysis than recommended, ranging from 10.4% to
45.8% more mean drops per bottle tested. This may indicate that manufacturers “overfill” the bottles to allow for a
margin of error during dispensing. If true, this serves an
important purpose, since it is known that many patients
require more than one eyedrop per application [9, 10].
However, this data suggests another problem has been created by this practice: significant variability in the number
of doses per bottle.
Aside from bottle volume, an additional factor influence the number of drops available per bottle is drop
size. We found significant variability in the estimated
drop size of studied formulations, ranging from 0.024 to
0.221 mL. The size of drop dispensed from a bottle
depends on three basic elements: the design of the dropper bottle and tip, properties of the contained solution
and the position of the bottle. The surface area around
the bottle tip and surface tension of the solution are
both manufacturer controlled factors that influence drop
size. Patient manipulations such as the angle and rate
drops are produced are less predictable [11]. Further, the
results of the current study and others suggest the most
economical bottle position varies from one design to the
next [17–19]. A final potential determinant of drop size
is the force required to squeeze the bottle, which unfortunately is significantly variable in both the experimental
and clinical setting [21, 22]. With all of these influences,
it may be difficult to design an ideal bottle for instillation. One expert suggestion has been to utilize a dropper
tip with a smaller outer orifice diameter that provides
consistent surface area for a smaller-volume drop to fall
[11].
This study has several limitations. The experimental
design was novel, and although measurements were
automated, they have not been independently verified.
Because the study was conducted in an objective and
reproducible manner, it may not accurately reflect many
of the patient related factors in dosing; it is likely that
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our patients experience even greater variability in the
number of drops available per bottle. Only two bottle
positions were tested and most ophthalmic containers
are not intended to be delivered in a strictly horizontal
position. While 192 bottles from 32 bottle designs were
tested, they still represent a small sampling of all available brand and generic ophthalmic medications.

Conclusion
In summary, this study demonstrates the significant variability in drops and volume available per bottle of glaucoma medication depending on both the bottle position
and manufacturer. This unregulated practice leaves prescribing physicians and pharmacists unable to accurately
predict the quantity of medication to dispense. This may
lead to patients running out of medication early or being
left with excess and associated costs. The variability from
one refill to the next could be a contributor to limited
compliance. The experimental design in this study indicates an objective, reproducible method to determine drop
number uniformly across different bottles and designs. It
should compel further evaluation and consideration of
standardization in the industry.
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